Greywolf Therapeutics reports durable clinical responses with first-in-class oral ERAP1 inhibitor GRWD5769 across six solid tumor types

Contributed by: GlobeNewswire

Tags

New cancer drug

More Like This

Greywolf Therapeutics and Genomics Launch Strategic Relationship to Develop First‑in‑Class Treatments for Autoimmune Diseases

Debiopharm Highlights Clinical Momentum Across DDR Portfolio at ESMO 2026, Advancing WEE1-Based Therapies in Ovarian and Uterine Cancers and Glioblastoma

PR Newswire associated0

Tagworks Pharmaceuticals Announces Initiation of Third Dose Level in Ongoing Phase 1 Clinical Trial of TGW101 for the Treatment of Solid Tumors

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

PR Newswire associated0

Qilu Pharmaceutical Showcases QL1706 Clinical Trial Outcomes in Oral Presentation at ESGO 2024

Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC

PR Newswire associated0

Tagworks Pharmaceuticals Announces FDA Clearance of IND Application and Initiation of Phase 1 Clinical Trial for TGW101 and Appoints Keith Orford, MD, PhD, as Chief Medical Officer

Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026